
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is a clinical stage metabolic therapeutics company with a novel approach to treating obesity and type 2 diabetes. The success of their lead product candidate, the Revita DMR System, has been demonstrated in both the REVEAL-1 and REVEAL-1 open-label extension (OLE) cohorts, with patients maintaining at least 5% of GLP-1-induced weight loss through one year. Fractyl's upcoming pivotal REMAIN-1 study is expected to further strengthen their position, with a mean total body weight loss of 18.3%. In addition, the company's RJVA-001 gene therapy for T2D has received CTA authorization in the Netherlands and is currently being evaluated in a Phase 1/2 clinical trial. With positive FDA feedback and the potential for accelerated coverage timelines via the RAPID pathway, Fractyl is positioned for success in the metabolic disease treatment market.
Bears say
Fractyl Health is projected to have a high chance of success in the weight maintenance market with its Revita program, and may see significant upside potential in both market penetration and geographic expansion opportunities. However, risks such as inconclusive clinical trials or funding difficulties could impede its progress towards commercialization. Initial findings for its trial data also appear promising with strong efficacy numbers, but a small sample size and shorter follow-up period may raise some concern. The positivity surrounding the company's potential is reflected in a Buy rating, but investors should remain cautious of potential risks.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares